title: Regulation of TH1/TH2 cytokine production by Chungsim-Yeunja-Tang in patients with cerebral infarction.
abstract: Chungsim-Yeunja-Tang is a prescription for the Taeumin cerebral infarction (CI) patients according to Sasang constitutional philosophy. Taeumin patients with CI were treated with CY-Tang during the acute stage. Clinical signs of CI disappeared markedly in about 2 weeks after oral administration of CY-Tang in all patients. The mean interleukin (IL)-2 plasma levels were slightly lower in the patients with CI than in the normal groups, whereas the mean TNF-alpha, IL-4, IL-6, and IgE levels were significantly higher in the patients with CI. There were no significant differences in interferon-gamma (IFN-gamma) levels between the groups. Serum IFN-gamma and IL-2 levels derived from (Th) 1 cells were significantly elevated in the patients with CI by CY-Tang administration. Significant reduced plasma levels of IL-4 and IL-6 derived from Th2 cells and IgE were observed in the patients treated with CY-Tang. Plasma levels TNF-alpha derived from Th1 significantly increased in the patients treated with CY-Tang. During the period of CY-Tang administration, there were no other adverse effects. The data indicate that CY-Tang has a good CI treatment effect, and that its action may be due to the regulation of cytokine production.
authors.affiliation: Department of Oriental Pharmacy, College of Pharmacy, Wonkwang University, Iksan-city, Chonbuk, South Korea.
authors.forename: Hyun-Ja
authors.initials: HJ
authors.lastname: Jeong
authors.forename: Sun-Yong
authors.initials: SY
authors.lastname: Seo
authors.forename: Hyun-Soo
authors.initials: HS
authors.lastname: Noh
authors.forename: Hye-Sun
authors.initials: HS
authors.lastname: Park
authors.forename: Jong-Deok
authors.initials: JD
authors.lastname: Lee
authors.forename: Kyung-Suk
authors.initials: KS
authors.lastname: Kim
authors.forename: Kwang-Ho
authors.initials: KH
authors.lastname: Cho
authors.forename: Kyung-Yo
authors.initials: KY
authors.lastname: Kim
authors.forename: Hyung-Min
authors.initials: HM
authors.lastname: Kim
mesh_terms: D000328:Adult; D000368:Aged; D002544:Cerebral Infarction / Q000188:drug therapy / Q000276:immunology*; D016207:Cytokines / Q000097:blood*; D004365:Drugs, Chinese Herbal / Q000494:pharmacology* / Q000627:therapeutic use; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood; D007371:Interferon-gamma / Q000097:blood; D007376:Interleukin-2 / Q000097:blood; D015847:Interleukin-4 / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D008297:Male; D008875:Middle Aged; D008517:Phytotherapy; D018417:Th1 Cells / Q000187:drug effects* / Q000378:metabolism; D018418:Th2 Cells / Q000187:drug effects* / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis
chemical_list: C487871:Chungsim-Yeunga-Tan; D016207:Cytokines; D004365:Drugs, Chinese Herbal; D007376:Interleukin-2; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D015847:Interleukin-4; D007073:Immunoglobulin E; D007371:Interferon-gamma